| Budget Amount *help |
¥18,590,000 (Direct Cost: ¥14,300,000、Indirect Cost: ¥4,290,000)
Fiscal Year 2010: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2009: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2008: ¥8,190,000 (Direct Cost: ¥6,300,000、Indirect Cost: ¥1,890,000)
|
|---|
| Research Abstract |
We reported in this study period that, through superinfection of cells with multiple HIV-1 strains and homologous recombination, HIV-1 can acquire high-level resistance against darunavir (DRV), to which HIV-1 hardly acquires resistance. We also identified cyclopentanyl-tetrahydrofuran-containing GRL-02031, which binds to HIV-1 protease in a bimodal way and exerts potent antiviral activity. Furthermore, we obtained GRL-0216A and -0286A with a macrocyclic ligand plus GRL-1388A and -1398A which contain a tetrahydropyrano-tetrahydrofuran moiety and exert potenta activity agaisnt multi-drug resistant varinats including DRV-resistant HIV-1 strains. We also ideintified GRL-0519A, which contains an oxatricyclic-tetrahydrofuran with potent anti-HIV activtiy agaisnt a wide spectrum of drug-resistant HIV-1s and potent activity to block the dimerization of HIV-1 portease monomers.
|
